Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

16.18
Delayed Data
As of Feb 24
 -0.40 / -2.41%
Today’s Change
13.00
Today|||52-Week Range
86.50
+11.43%
Year-to-Date
Berkshire Letter Highlights: Buffett Hates Hedge Funds, Likes Immigrants And The US O...
Feb 25 / Investing Channel - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Alle...
Feb 21 / Zacks.com - Paid Partner Content
Saba Capital Management, L.P. Buys Allergan PLC, Alpine Total Dynamic Dividend Fund, ...
Feb 23 / GuruFocus News - Paid Partner Content
This Guru Loves Valeant; Should You?
Feb 20 / GuruFocus News - Paid Partner Content
Allergan Lacks Interest in Valeant
Feb 23 / TheStreet.com - Paid Partner Content
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
Feb 17 / Zacks.com - Paid Partner Content
Frontrunning: February 23
Feb 23 / Investing Channel - Paid Partner Content
It Happened Again! Another Drugmaker Got Caught With an Exorbitant Price Hike
Feb 17 / MotleyFool.com - Paid Partner Content
Futures Flat, Global Stocks Near Record High After Minutes Fail To Spark Dollar Rally
Feb 23 / Investing Channel - Paid Partner Content
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb 17 / Zacks.com - Paid Partner Content
Silver Point Capital L.P. Buys Basic Energy Services, Key Energy Services, Penn Virgi...
Feb 22 / GuruFocus News - Paid Partner Content
Don't Count on Valeant's New Drug to Save the Day
Feb 16 / MotleyFool.com - Paid Partner Content
Valeant Acquires Eyegate Licensing Rights
Feb 21 / TheStreet.com - Paid Partner Content
These 3 Hedge Funds Are Playing With Fire
Feb 15 / MotleyFool.com - Paid Partner Content